Acurx Pharmaceuticals (ACXP) Enterprise Value (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Enterprise Value came in at -$9.3 million in Q1 2026, down 99.29% YoY from -$1.3 billion in Q1 2025, and down 22.48% on a QoQ basis from -$7.6 million in Q4 2025.
Acurx Pharmaceuticals (ACXP) Enterprise Value (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Enterprise Value data on file, last reported at -$9.3 million in Q1 2026.
- Quarterly Enterprise Value fell 99.29% year-over-year to -$9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.3 million (down 99.29% YoY) and the FY2025 annual result came in at -$7.6 million, down 103.85% from the prior year.
- Enterprise Value slipped to -$9.3 million in Q1 2026, from -$7.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$3.7 million in Q4 2024 to a low of -$11.1 million in Q1 2022.
- A 5-year average of -$7.6 million and a median of -$7.5 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value tumbled 321.68% — and 2024, when it jumped 50.41%.
- Tracing ACXP's Enterprise Value over 5 years: stood at -$9.1 million in 2022, then grew by 17.97% to -$7.5 million in 2023, then jumped by 50.41% to -$3.7 million in 2024, then sank by 103.85% to -$7.6 million in 2025, then slipped by 22.48% to -$9.3 million in 2026.
- The last three Enterprise Value figures came in at -$9.3 million (Q1 2026), -$7.6 million (Q4 2025), and -$5.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Acurx Pharmaceuticals | 6.38 Mn | 6.38 Mn | - | -10.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.70 Mn |
| Mar 31, 2026 | -9.25 Mn |
| Dec 31, 2025 | -7.56 Mn |
| Sep 30, 2025 | -5.91 Mn |
| Jun 30, 2025 | -6.06 Mn |
| Mar 31, 2025 | -4.64 Mn |
| Dec 31, 2024 | -3.71 Mn |
| Sep 30, 2024 | -5.76 Mn |
| Jun 30, 2024 | -6.36 Mn |
| Mar 31, 2024 | -8.92 Mn |
| Dec 31, 2023 | -7.47 Mn |
| Sep 30, 2023 | -7.05 Mn |
| Jun 30, 2023 | -9.15 Mn |
| Mar 31, 2023 | -7.18 Mn |
| Dec 31, 2022 | -9.11 Mn |
| Sep 30, 2022 | -10.61 Mn |
| Jun 30, 2022 | -9.09 Mn |
| Mar 31, 2022 | -11.08 Mn |
| Dec 31, 2021 | -12.96 Mn |
| Sep 30, 2021 | -14.46 Mn |